Uma Kher

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Kohei Shitara, Eric Van Cutsem, Yung‐Jue Bang et al. · JAMA Oncology · 2020 · 1.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Combined modality therapy for primary CNS lymphoma.

Lisa M. DeAngelis, Joachim Yahalom, H Thaler et al. · Journal of Clinical Oncology · 1992 · 544 citations

Medicine, Oncology, Central Nervous System Radiation Oncology +10

Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling

Charles H. Chesnut, Michael R. McClung, Kristine E. Ensrud et al. · The American Journal of Medicine · 1995 · 367 citations

Medicine, Endocrinology, Bone Metabolism +14

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

Medicine, Oncology, Pharmacology +12

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis

Joseph Tucci, Richard P. Tonino, Ronald Emkey et al. · The American Journal of Medicine · 1996 · 222 citations

Medicine, Endocrinology, Bone Metabolism +10